Highlights

  • NX1 shares rose 18.18% to $0.013.
  • Last-patient-last-dose in the Phase 1 study of IRX-616a was completed in May 2026.
  • A binding letter of intent for replacement financing was secured.
  • The company returned to official quotation.

Nexalis Therapeutics Ltd (ASX:NX1) shares climbed 18.18% to $0.013 on 10 September 2026. Nexalis Therapeutics is progressing a clinical-stage drug-development portfolio focused on pain and mental-health conditions. A key recent milestone was completion of last-patient-last-dose in the Phase 1 clinical study of IRX-616a in May 2026. The company also secured a binding letter of intent relating to replacement financing and returned to official quotation. Investors remain focused on clinical data and subsequent development decisions.

Sector Context

Clinical-stage biotechs developing pain and mental-health therapies continue to rely on trial milestones and financing arrangements to progress their pipelines, with Quotation status and funding structure closely watched by the market.

Risks to Consider

Clinical Drug Development carries inherent trial and regulatory risk. Reliance on further financing, along with the outcome of Phase 1 data, will shape the company's next steps. Trading in early-stage biotech shares can be volatile.

What to Watch Next

Investors will be watching for the release of Phase 1 clinical data from the IRX-616a study and further details on the replacement financing arrangement.

Conclusion

With Phase 1 dosing complete and financing arrangements progressing, Nexalis Therapeutics' next milestone will be the release of clinical trial data.